Sanara MedTech initiated with a Buy at Lake Street

Lake Street initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $32 price target The firm, which estimates Sanara generates $116M of revenue with 14% AEBITDA margins for 2026, thinks the Street is “misunderstanding the strategic pivot” to being a pure-play surgical wound company focused on the operating room setting and argues that the emergence of the company’s growth and leverage profile will drive share upside.